$AMLX
BEARISH2022-03-28By horizon✓ hit-10.5%
1d
✗ +0.7%
5d
✓ -6.0%
21d
✓ -10.5%
Original post
Andy Biotech · 2022-03-28
$AMLX My quick take on FDA AdCom briefing doc Good news: No bombshell surprise. Bad news: The most appealing point of this drug to patients is the purported survival benefit, but FDA clearly doesn't buy into the claim due to multiple issues. https://t.co/phSXKsR3ig
View on X ↗